Patents by Inventor Desire Collen

Desire Collen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9085617
    Abstract: The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: July 21, 2015
    Assignees: THROMBOGENICS N.V., VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW, LIFE SCIENCES RESEARCH PARTNERS VZW
    Inventors: Jean-Marie Stassen, Peter Carmeliet, Desire Collen
  • Publication number: 20140178397
    Abstract: The present invention provides novel monoclonal antibodies directed to P1GF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.
    Type: Application
    Filed: February 3, 2014
    Publication date: June 26, 2014
    Inventors: Jean-Marie STASSEN, Peter CARMELIET, Desire COLLEN
  • Patent number: 8758748
    Abstract: The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: June 24, 2014
    Assignees: Thrombogenics N.V., VLAAMS Interuniversitair Instituut voor Biotechnologie VZW, Life Sciences Research Partners VZW
    Inventors: Jean-Marie Stassen, Peter Carmeliet, Désiré Collen
  • Publication number: 20130183310
    Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monocloncal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.
    Type: Application
    Filed: March 5, 2013
    Publication date: July 18, 2013
    Inventors: Peter Carmeliet, Desire Collen, Sandro De Falco, Ruvo Menotti
  • Publication number: 20130177564
    Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monocloncal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.
    Type: Application
    Filed: March 5, 2013
    Publication date: July 11, 2013
    Inventors: Peter CARMELIET, Desire Collen, Sandro De Falco, Ruvo Menotti
  • Publication number: 20130177565
    Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monocloncal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.
    Type: Application
    Filed: March 5, 2013
    Publication date: July 11, 2013
    Applicants: LIFE SCIENCES RESEARCH PARTNERS VZW (LSRP), VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (VIB)
    Inventors: Peter CARMELIET, Desire Collen, Sandro De Falco, Ruvo Menotti
  • Publication number: 20120263710
    Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monocloncal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.
    Type: Application
    Filed: May 14, 2012
    Publication date: October 18, 2012
    Applicants: LIFE SCIENCES RESEARCH PARTNERS VZW (LSRP), VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (VIB)
    Inventors: Peter CARMELIET, Désiré Collen, Sandro De Falco, Ruvo Menotti
  • Publication number: 20110288020
    Abstract: The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion in the hypoxia responsive element (HRE) of the VEGF promoter which alters the hypoxic upregulation of VEGF. These mice suffer severe adult onset muscle weakness due to progressive spinal motor neuron degeneration which is reminiscent of amyotrophic lateral sclerosis (ALS)—a fatal disorder with unknown aetiology. Furthermore, the neuropathy of these mice is not caused by vascular defects, but is due to defective VEGF-mediated survival signals to motor neurons.
    Type: Application
    Filed: December 3, 2010
    Publication date: November 24, 2011
    Inventors: Peter Carmeliet, Désiré Collen, Bert Oosthuyse
  • Publication number: 20110123525
    Abstract: The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.
    Type: Application
    Filed: December 20, 2010
    Publication date: May 26, 2011
    Inventors: Jean-Marie Stassen, Peter Carmeliet, Désiré Collen
  • Patent number: 7888322
    Abstract: The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion in the hypoxia responsive element (HRE) of the VEGF promoter which alters the hypoxic upregulation of VEGF. These mice suffer severe adult onset muscle weakness due to progressive spinal motor neuron degeneration which is reminiscent of amyotrophic lateral sclerosis (ALS)—a fatal disorder with unknown aetiology. Furthermore, the neuropathy of these mice is not caused by vascular defects, but is due to defective VEGF-mediated survival signals to motor neurons.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: February 15, 2011
    Assignees: Vlaams Interuniversitair Instituut voor Biotechnologie VZW, Life Sciences Research Partners VZW
    Inventors: Peter Carmeliet, Désiré Collen, Bert Oosthuyse
  • Patent number: 7875704
    Abstract: The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: January 25, 2011
    Assignees: Vlaams Interuniversitair Instituut voor Biotechnologie VZW, Life Sciences Research Partners VZW, Thrombogenics N.V.
    Inventors: Jean-Marie Stassen, Peter Carmeliet, Désiré Collen
  • Patent number: 7727971
    Abstract: The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor or nucleic acids ensuring increased expression of a growth factor for treating, more particularly restoring the function of ischemic tissue, in particular muscles such as myocardium and skeletal muscles.
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: June 1, 2010
    Assignees: Life Sciences Research Partners VZW, Flanders Interuniversity Institute for Biotechnology (VIB)
    Inventors: Peter Carmeliet, Désiré Collen
  • Patent number: 7709450
    Abstract: VEGF-B is shown to be needed for cardiac muscle revascularization after heart infarction, and methods of promoting or stimulating vascular development, e.g. angiogenesis and/or arteriogenesis, particularly in ischemic mammals, are disclosed.
    Type: Grant
    Filed: June 20, 2002
    Date of Patent: May 4, 2010
    Assignees: Ludwig Institute for Cancer Research, Flanders Interuniversity Institute for Biotechnology
    Inventors: Ulf Eriksson, Xuri Li, Peter Carmeliet, Desire Collen
  • Publication number: 20100041601
    Abstract: The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion in the hypoxia responsive element (HRE) of the VEGF promoter which alters the hypoxic upregulation of VEGF. These mice suffer severe adult onset muscle weakness due to progressive spinal motor neuron degeneration which is reminiscent of amyotrophic lateral sclerosis (ALS)—a fatal disorder with unknown aetiology. Furthermore, the neuropathy of these mice is not caused by vascular defects, but is due to defective VEGF-mediated survival signals to motor neurons.
    Type: Application
    Filed: November 19, 2008
    Publication date: February 18, 2010
    Inventors: Peter Carmeliet, Désiré Collen, Bert Oosthuyse
  • Publication number: 20090238826
    Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monocloncal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.
    Type: Application
    Filed: March 10, 2009
    Publication date: September 24, 2009
    Applicants: VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (VIB), LIFE SCIENCES RESEARCH PARTNERS VZW (LSRP)
    Inventors: Peter CARMELIET, Desire Collen, Sandro De Falco, Ruvo Menotti
  • Patent number: 7592314
    Abstract: The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion in the hypoxia responsive element (HRE) of the VEGF promoter which alters the hypoxic upregulation of VEGF. These mice suffer severe adult onset muscle weakness due to progressive spinal motor neuron degeneration which is reminiscent of amyotrophic lateral sclerosis (ALS)—a fatal disorder with unknown aetiology. Furthermore, the neuropathy of these mice is not caused by vascular defects, but is due to defective VEGF-mediated survival signals to motor neurons.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: September 22, 2009
    Assignees: Viaams Interuniversitair Instituut voor Biotechnologie VZW, Life Sciences Research PartnersVZW
    Inventors: Peter Carmeliet, Désiré Collen, Bert Oosthuyse
  • Publication number: 20090162354
    Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monoclonal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.
    Type: Application
    Filed: December 22, 2008
    Publication date: June 25, 2009
    Applicants: VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (VIB), LIFE SCIENCES RESEARCH PARTNERS VZW (LSRP)
    Inventors: Peter CARMELIET, Desire COLLEN, Sandro DE FALCO, Ruvo MENOTTI
  • Publication number: 20090074765
    Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monoclonal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.
    Type: Application
    Filed: November 5, 2008
    Publication date: March 19, 2009
    Applicants: VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (VIB), LIFE SCIENCES RESEARCH PARTNERS VZW (LSRP)
    Inventors: Peter CARMELIET, Desire Collen, Sandro De Falco, Ruvo Menotti
  • Patent number: 7482004
    Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monoclonal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.
    Type: Grant
    Filed: November 11, 2002
    Date of Patent: January 27, 2009
    Assignees: Vlaams Interuniversitair Instituut voor Biotechnologie vzw, Life Sciences Research Partners vzw.
    Inventors: Peter Carmeliet, Désiré Collen, Sandro De Falco, Ruvo Menotti
  • Publication number: 20080193455
    Abstract: The present invention provides novel monoclonal antibodies directed to P1GF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.
    Type: Application
    Filed: March 24, 2006
    Publication date: August 14, 2008
    Inventors: Jean-Marie Stassen, Peter Carmeliet, Desire Collen